| Patient | Isaac Newton |
|---|---|
| Date of birth | 1643-01-04 |
| Identifiers | MRN HR-EN011-SYN-TD; SSN (made up) 000-11-6840 |
| Document date | 1693-10-29 |
| Author | Rupert Okonkwo-Fairbanks, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-week depression and mercury exposure review. [S]
Mr. Newton returns three weeks after starting sertraline 50 mg and a month after removal from exposure. Mild nausea in the first few days settled; he has had no other side effects and has missed no doses. He has had three sessions of cognitive behavioral therapy. He sleeps about five and a half hours, keeps the sleep window, and no longer dozes in the evening. He eats three meals a day. He has written to apologize to the friends he accused and has had warm replies; he no longer believes anyone was plotting against him. He is teaching fully and has begun to answer letters again. He has had no thoughts of death or of harming himself or anyone else. The safety office has not yet re-measured the laboratory after its cleaning, so it remains closed. He brought his 24-hour urine collection this morning. [S]
| Element | Detail |
|---|---|
| Medication | Sertraline 50 mg for three weeks; no side effects now |
| Psychotherapy | Three CBT sessions |
| Sleep | About five and a half hours; no evening dozing |
| Suspicious ideas | Resolved; apologies made and accepted |
| Exposure | None for a month; laboratory still closed |
| PHQ-9 | 14, down from 20 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Appetite better; weight 64.8 kg |
| Ears, nose, mouth, and throat | Negative | No gum or mouth symptoms |
| Neurological | Negative | No tremor, numbness, or headache |
| Psychiatric | Positive | Mood lifting but still low most mornings; no suicidal thoughts, elevated mood, or agitation |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sertraline 50 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 1693-10-08 | active | S |
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours as needed for aches or fever, no more than 3 g a day | One or two tablets every 6 hours as needed; no more than six tablets a day | Oral route | 1693-10-15 to 1693-10-22 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1693-10-29 | Body height | 170 | cm | S |
| 1693-10-29 | Body weight | 64.8 | kg | S |
| 1693-10-29 | Body mass index (BMI) [Ratio] | 22.4 | kg/m2 | S |
| 1693-10-29 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1693-10-29 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1693-10-29 | Heart rate | 72 | /min | S |
| 1693-10-29 | Respiratory rate | 14 | /min | S |
| 1693-10-29 | Body temperature | 36.6 | Cel | S |
| 1693-10-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1693-10-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 14 | {score} | S | ||
| 1693-10-29 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | {score} | S | ||
| 1693-10-29 | Mercury [Mass/volume] in Blood | 3.1 | ug/L | 95th percentile of US adults below 5 ug/L (ATSDR); 50 ug/L or more is the threshold for symptoms of toxicity | Normal | S |
| 1693-10-29 | Mercury [Mass/volume] in 24 hour Urine | 31 | ug/L | Background below 2 ug/L (95th percentile of adults); below 20 ug/L not associated with effects (ATSDR) | High | S |
| 1693-10-29 | Mercury/Creatinine [Mass Ratio] in 24 hour Urine | 27 | ug/g{creat} | Occupational biological exposure index 20 ug/g creatinine | High | S |
Vital signs recorded on 1693-10-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Better color; tidier |
| Mouth | Gums healthy |
| Neurological | No tremor; spiral drawing normal |
| Mental status | Engaged, at times humorous; mood "lighter"; affect more reactive; no suspicious or fixed false beliefs; no suicidal or homicidal ideation |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| A year of poor sleep and poor appetite with 4 kg weight loss, two weeks of near-total sleeplessness, low spirits, and suspicious thoughts that colleagues and friends were plotting against him, now partly doubted; under evaluation for depression, a toxic cause, and other medical causes | resolved | confirmed | R45.89 | S — Synthetic presenting concern echoing the poor sleep, poor appetite, distress, and retracted suspicions documented in his letters of September 1693; superseded by the diagnoses at the second visit. |
| Occupational exposure to elemental and inorganic mercury, with lesser exposure to lead, antimony, and arsenic compounds, from heating metals in an unventilated private laboratory | active | confirmed | Z57.5 | S — Synthetic modern exposure echoing his documented chemical and alchemical work with metals, including mercury; no level of historical exposure is asserted. |
| Major depressive disorder, single episode, severe, without psychotic features (PHQ-9 20 at intake): a year of poor sleep and appetite with weight loss, low mood, poor concentration, and suspicious ideas held with partial insight; medical causes excluded; the contribution of low-level mercury exposure is uncertain | active | confirmed | F32.2 | S — Synthetic modern diagnosis. His sleeplessness, poor appetite, distress, and melancholy in 1693 are documented (D); calling them major depression is a modern reading, and mercury poisoning and other explanations proposed later are disputed (R). |
| Chronic insomnia comorbid with depression: sleep onset and maintenance difficulty for a year, with two weeks of near-total sleeplessness before intake | active | confirmed | G47.00 | S — Synthetic diagnosis echoing his documented sleeplessness. |
| Raised urine mercury from occupational exposure (24-hour urine 46 ug/L, 41 ug/g creatinine; blood 9.4 ug/L) without tremor, gingivitis, erethism, neuropathy, or kidney injury; below the levels linked to overt toxicity | active | confirmed | R82.6 | S — Synthetic result echoing his documented work with mercury; it does not assert that he was poisoned (see CLM-0011, R, disputed). |
| Acute viral upper respiratory infection (common cold) with a low-grade fever, sore throat, and cough, a week after starting sertraline; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness at an unscheduled visit; it echoes, without asserting, his documented mention of a distemper that was epidemical that summer (CLM-0008). |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 14, down from 20 (30 percent); item 9 scored 0 |
| Survey | GAD-7 | With the PHQ-9 when anxiety accompanies depression | Completed today | 7, down from 11 |
| Survey | Suicide and violence risk reassessment (C-SSRS Since Last Visit, PHQ-9 item 9, and thoughts of harming others) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior; no thoughts of harming others; PHQ-9 item 9 scored 0 |
| Medication safety | SSRI tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Completed today | Done at the preventive visit two weeks after the start (no side effects) and again today |
| Medication safety | Adherence and adverse-effect review | Every visit during active treatment | Completed today | No missed doses; early nausea resolved; no bleeding, restlessness, or sexual side effects |
| Laboratory | 24-hour urine mercury with creatinine correction, and blood mercury | At the exposure assessment, then 4 to 6 weeks after removal and at 3 months | Completed today | Urine 31 ug/L and 27 ug/g creatinine, falling; blood 3.1 ug/L, normal; next at three months |
| Laboratory | Kidney function and urine protein | At the exposure assessment and at 3 months | Due | Normal at intake; due at three months |
| Examination | Signs of mercury toxicity: tremor (postural and intention), handwriting, gums and mouth, erethism, peripheral neuropathy | At the exposure assessment and at each follow-up while levels are raised | Completed today | No tremor, gingivitis, or neuropathy |
| Self-management | Workplace hazard control: re-measurement of mercury vapor after decontamination | After decontamination and before any return to the laboratory | Deferred | Missed: the safety office planned to re-measure the laboratory within two weeks of cleaning, but has not yet done so. No harm: the laboratory has stayed closed, he has had no exposure, and his urine mercury is falling. Corrective action: the clinic wrote to the safety office asking for the measurement and the fume-hood installation date, and his return to laboratory work stays on hold until both are confirmed |
| Medication safety | Chelation and provoked (chelator-challenge) urine testing | Only for symptomatic patients with high levels, decided with a medical toxicologist | Not indicated | Urine mercury below 100 ug/L with no tremor, gingivitis, or kidney injury; removal from exposure comes first, and provoked testing is not valid |
| Examination | Weight and nutrition | Every visit while weight is below his usual | Completed today | 64.8 kg, up 1.0 kg since the diagnosis visit; three meals a day |
| Self-management | Psychotherapy, sleep, and activity | Every visit during active treatment | Completed today | Three CBT sessions; sleep window widened; teaching fully; walks most days |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Treated with an SSRI only; no antipsychotic, because there are no psychotic features |
Goal progress:
Guideline basis: CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016); Evaluating Mercury Exposure: Information for Health Care Providers (2018); NIOSH Pocket Guide to Chemical Hazards: Mercury compounds [except (organo) alkyls] (as Hg) (2026); American College of Medical Toxicology Position Statement on Post-Chelator Challenge Urinary Metal Testing (2010); Use and Misuse of Metal Chelation Therapy (McKay CA, editorial) and Recommendations for Provoked Challenge Urine Testing (Ruha AM), proceedings of the ACMT symposium (2013)
Follow-up: Depression review in three weeks; urine mercury and kidney tests at three months; second zoster dose in two to six months. [S]